FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3023772723> ?p ?o ?g. }

• W3023772723 endingPage "e1149" @default.
• W3023772723 startingPage "e1148" @default.
• W3023772723 abstract "INTRODUCTION AND OBJECTIVE: It is well known that mp-MRI of the prostate is associated with a high negative predictive value (NPV) for clinically significant prostate cancer (csPCa). However, not in all studies negative mp-MRI had negative back-up histology. Moreover, there is a lack of strong data on follow-up in men with initial negative evaluation. The aim of this study was to assess the outcome over time of men with negative mp-MRI and a proven absence of PCa at initial systematic biopsy. METHODS: We evaluated 250 patients with negative mp-MRI (PIRADS 1 or 2) and a concomitant negative systematic prostate biopsy performed at a single tertiary care referral centre between 2016 and 2017. All patients were submitted to 1.5 MRI study using an endorectal coil which was interpreted by two expert radiologists. After negative imaging and biopsy, all patients were then followed with annual serial PSA measurement and digital rectal examination (DRE). In case of suspicion for PCa (rising PSA and/or positive DRE), follow-up mp-MRI and/or prostate biopsy (Bx) were performed. The study outcome was csPCa (defined as Gleason score at biopsy≥3+4) during follow-up. Kaplan Meier analysis was used to assess csPCa diagnosis-free survival. Using multivariable Cox regression analysis (MVA) we investigated eventual predictors of presence of csPCa at follow-up using the following covariates: age at biopsy, PSA density and clinical stage (T1 vs T2 vs T3). RESULTS: Median follow-up was 30 months (IQR: 23-41). During the study period, 49 men (19.6%) underwent mp-MRI and 41 (16.4%) received a follow-up Bx. Overall, 5% (13/250) patients had positive MRI (PI-RADS 3-5) over time. Of all patients, 33 (13.2%) and 13 (5.2%) had any PCa and csPCa, respectively at follow-up after initial negative mp-MRI. The 2-, 3- and 4-year csPCa diagnosis-free survival were 94.6, 87.8 and 86%, respectively. Diagnosis-free survival probability for csPCa was unchanged after 48 months of follow-up onwards. At MVA, none of the predictors investigated was significantly associated with csPCa findings during follow-up in men with initial negative mpMRI (all p≥0.1). CONCLUSIONS: We demonstrated that only a minority of patients (5%) with initial negative mpMRI and concomitant negative Bx developed csPCa at a median follow-up of 30 months, suggesting how the high initial NPV of mp-MRI is maintained over time. These findings support the importance of initial negative mp-MRI in ruling out csPCa over time provided a negative initial biopsy. Source of Funding: none" @default.
• W3023772723 created "2020-05-13" @default.
• W3023772723 creator A5009772028 @default.
• W3023772723 creator A5011155325 @default.
• W3023772723 creator A5022352601 @default.
• W3023772723 creator A5023266580 @default.
• W3023772723 creator A5027612338 @default.
• W3023772723 creator A5031548152 @default.
• W3023772723 creator A5031550729 @default.
• W3023772723 creator A5039363062 @default.
• W3023772723 creator A5042911985 @default.
• W3023772723 creator A5043298513 @default.
• W3023772723 creator A5044228660 @default.
• W3023772723 creator A5058036624 @default.
• W3023772723 creator A5060697265 @default.
• W3023772723 creator A5061623935 @default.
• W3023772723 creator A5067303296 @default.
• W3023772723 creator A5071443011 @default.
• W3023772723 creator A5078216208 @default.
• W3023772723 creator A5078520876 @default.
• W3023772723 creator A5078963360 @default.
• W3023772723 creator A5079987260 @default.
• W3023772723 creator A5083331837 @default.
• W3023772723 creator A5083351538 @default.
• W3023772723 date "2020-04-01" @default.
• W3023772723 modified "2023-10-16" @default.
• W3023772723 title "MP75-18 INITIAL NEGATIVE MULTI-PARAMETRIC MRI WITH CONCOMITANT NEGATIVE BIOPSY" @default.
• W3023772723 doi "https://doi.org/10.1097/ju.0000000000000961.018" @default.
• W3023772723 hasPublicationYear "2020" @default.
• W3023772723 type Work @default.
• W3023772723 sameAs 3023772723 @default.
• W3023772723 citedByCount "0" @default.
• W3023772723 crossrefType "journal-article" @default.
• W3023772723 hasAuthorship W3023772723A5009772028 @default.
• W3023772723 hasAuthorship W3023772723A5011155325 @default.
• W3023772723 hasAuthorship W3023772723A5022352601 @default.
• W3023772723 hasAuthorship W3023772723A5023266580 @default.
• W3023772723 hasAuthorship W3023772723A5027612338 @default.
• W3023772723 hasAuthorship W3023772723A5031548152 @default.
• W3023772723 hasAuthorship W3023772723A5031550729 @default.
• W3023772723 hasAuthorship W3023772723A5039363062 @default.
• W3023772723 hasAuthorship W3023772723A5042911985 @default.
• W3023772723 hasAuthorship W3023772723A5043298513 @default.
• W3023772723 hasAuthorship W3023772723A5044228660 @default.
• W3023772723 hasAuthorship W3023772723A5058036624 @default.
• W3023772723 hasAuthorship W3023772723A5060697265 @default.
• W3023772723 hasAuthorship W3023772723A5061623935 @default.
• W3023772723 hasAuthorship W3023772723A5067303296 @default.
• W3023772723 hasAuthorship W3023772723A5071443011 @default.
• W3023772723 hasAuthorship W3023772723A5078216208 @default.
• W3023772723 hasAuthorship W3023772723A5078520876 @default.
• W3023772723 hasAuthorship W3023772723A5078963360 @default.
• W3023772723 hasAuthorship W3023772723A5079987260 @default.
• W3023772723 hasAuthorship W3023772723A5083331837 @default.
• W3023772723 hasAuthorship W3023772723A5083351538 @default.
• W3023772723 hasConcept C121608353 @default.
• W3023772723 hasConcept C126322002 @default.
• W3023772723 hasConcept C126838900 @default.
• W3023772723 hasConcept C126894567 @default.
• W3023772723 hasConcept C141071460 @default.
• W3023772723 hasConcept C143409427 @default.
• W3023772723 hasConcept C2775934546 @default.
• W3023772723 hasConcept C2776235491 @default.
• W3023772723 hasConcept C2779384505 @default.
• W3023772723 hasConcept C2779466945 @default.
• W3023772723 hasConcept C2780101318 @default.
• W3023772723 hasConcept C2780192828 @default.
• W3023772723 hasConcept C2781217009 @default.
• W3023772723 hasConcept C50382708 @default.
• W3023772723 hasConcept C71924100 @default.
• W3023772723 hasConceptScore W3023772723C121608353 @default.
• W3023772723 hasConceptScore W3023772723C126322002 @default.
• W3023772723 hasConceptScore W3023772723C126838900 @default.
• W3023772723 hasConceptScore W3023772723C126894567 @default.
• W3023772723 hasConceptScore W3023772723C141071460 @default.
• W3023772723 hasConceptScore W3023772723C143409427 @default.
• W3023772723 hasConceptScore W3023772723C2775934546 @default.
• W3023772723 hasConceptScore W3023772723C2776235491 @default.
• W3023772723 hasConceptScore W3023772723C2779384505 @default.
• W3023772723 hasConceptScore W3023772723C2779466945 @default.
• W3023772723 hasConceptScore W3023772723C2780101318 @default.
• W3023772723 hasConceptScore W3023772723C2780192828 @default.
• W3023772723 hasConceptScore W3023772723C2781217009 @default.
• W3023772723 hasConceptScore W3023772723C50382708 @default.
• W3023772723 hasConceptScore W3023772723C71924100 @default.
• W3023772723 hasLocation W30237727231 @default.
• W3023772723 hasOpenAccess W3023772723 @default.
• W3023772723 hasPrimaryLocation W30237727231 @default.
• W3023772723 hasRelatedWork W1570285055 @default.
• W3023772723 hasRelatedWork W1979374145 @default.
• W3023772723 hasRelatedWork W2099948048 @default.
• W3023772723 hasRelatedWork W2102167265 @default.
• W3023772723 hasRelatedWork W2143331076 @default.
• W3023772723 hasRelatedWork W2168798245 @default.
• W3023772723 hasRelatedWork W2169738785 @default.
• W3023772723 hasRelatedWork W2409990396 @default.
• W3023772723 hasRelatedWork W2735172787 @default.
• W3023772723 hasRelatedWork W99274037 @default.

• next